PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)
Status:
Active, not recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This investigator driven study will examine the safety, tolerability and efficacy of the
combination of 177Lutetium-PSMA (177Lu-PSMA) and pembrolizumab in patients with metastatic
Castration Resistant Prostate Cancer (mCRPC). 177Lu-PSMA is a compound that binds to the
extra-cellular domain of the prostate-specific membrane antigen. Pembrolizumab is an antibody
targeted against anti-programmed cell death 1 (PD-1).This is a single arm study where all
patients will be treated with 177Lu-PSMA for upto 6 doses and pembrolizumab for upto 35
cycles.